...
首页> 外文期刊>The American Journal of Gastroenterology >A randomized controlled trial of an integrated care intervention to increase eligibility for chronic hepatitis C treatment.
【24h】

A randomized controlled trial of an integrated care intervention to increase eligibility for chronic hepatitis C treatment.

机译:一项综合护理干预措施以提高慢性丙型肝炎治疗资格的随机对照试验。

获取原文
获取原文并翻译 | 示例

摘要

OBJECTIVES: Mental health and substance abuse (MH/SA) comorbidities are the most oft-cited reasons for deferral from peginterferon (PegIFN) therapy for chronic hepatitis C virus (HCV). We sought to determine whether an integrated care intervention (INT) for patients deferred from PegIFN owing to MH/SA could improve subsequent treatment eligibility rates. METHODS: In this randomized controlled trial, 101 HCV patients who were evaluated at two hepatology centers and deferred from antiviral therapy owing to MH/SA were enrolled. Participants were randomized to an INT (N=50) or standard of care (SC; N=51). The INT group received counseling and case management for up to 9 months. All participants underwent 3-, 6-, and 9-month clinical follow-up visits, where hepatologists, masked to group, re-evaluated patients for treatment eligibility. Standardized mood and alcohol use instruments were administered to all participants to aid clinicians in treatment decisions. RESULTS: Of 101 participants, the mean age was 48 years and 50% were men, 61% Caucasian, and 77% genotype 1. Patients were initially deferred owing to psychiatric issues (35%), alcohol abuse (31%), drug abuse (9%), or more than one of these reasons (26%). In an intent-to-treat analysis, 42% (21/50) of INT participants became eligible for therapy compared to 18% (9/51) of SC participants (P=0.009, relative risk (RR)=2.38, 95% confidence interval (CI) (1.21, 4.68)). When baseline predictors significant at P<0.10 in univariate models were entered into multivariate models adjusted for treatment group, only baseline depression remained significant (P=0.05, RR=0.98, 95% CI (0.96, 1.00)). With the exception of a model adjusted for genotype, treatment group remained significant in all models. CONCLUSIONS: This trial suggests that INTs can increase eligibility for HCV treatment and expand treatment to the underserved population with MH/SA comorbidities.
机译:目的:心理健康和药物滥用(MH / SA)合并症是推迟使用聚乙二醇干扰素(PegIFN)治疗慢性丙型肝炎病毒(HCV)的最常见原因。我们试图确定针对因MH / SA而被PegIFN推迟治疗的患者的综合护理干预(INT)是否可以提高随后的治疗合格率。方法:在该随机对照试验中,招募了101名HCV患者,这些患者在两个肝病学中心进行了评估,并因MH / SA而推迟了抗病毒治疗。将参与者随机分为INT(N = 50)或护理标准(SC; N = 51)。廉政局小组接受了长达9个月的咨询和案件管理。所有参与者均接受了3个月,6个月和9个月的临床随访,其中,面罩成组的肝科医生对患者的治疗资格进行了重新评估。为所有参与者提供了标准化的情绪和饮酒工具,以帮助临床医生做出治疗决策。结果:101名参与者中,平均年龄为48岁,男性为50%,白种人为61%,基因型1为77%。患者最初因精神病学原因(35%),酗酒(31%),药物滥用而推迟(9%),或以上原因之一(26%)。在意向治疗分析中,有42%(21/50)的INT参与者有资格接受治疗,而SC参与者的这一比例为18%(9/51)(P = 0.009,相对风险(RR)= 2.38,95%置信区间(CI)(1.21、4.68))。当将单变量模型中的基线预测指标在P <0.10时显着纳入针对治疗组进行调整的多变量模型中时,仅基线抑郁症仍然显着(P = 0.05,RR = 0.98,95%CI(0.96,1.00))。除了针对基因型调整的模型外,治疗组在所有模型中均保持显着水平。结论:该试验表明,INTs可以增加HCV治疗的资格,并将治疗范围扩大到MH / SA合并症的服务不足的人群。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号